UNSPSC 51432104: Guanethidine

This classification denotes an antihypertensive agent with the molecular formula C10H22N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTI6C33Q2Q, chemically known as 2-(1-n,n-heptamethyleneimino)ethylguanidine but generally known as guanethidine, which bears US NIH Compound Identifier 3518. European Medicines Agency schedules Guanethidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07984MIG.

UNSPSC 51432104 Guanethidine is a Commodity code covering individual pharmaceutical products purchased by state and local health agencies, fire-rescue departments, and cooperative purchasing consortia. State and local governments buy branded and generic pharmaceuticals under this code for emergency medical services, hospital formularies, public health programs, and employee health plans. Recent solicitations show purchasing spanning emergency-response medications, multi-source generic drugs for state facility distribution networks, and direct-to-manufacturer prescription programs. Issuing bodies include municipal fire-rescue departments (City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). The purchasing mix reflects both direct municipal procurement and statewide coordinated purchasing vehicles that aggregate demand across state agencies and local member jurisdictions.

Geographic activity centers on Texas, Minnesota (with participating states including Oregon), and Florida. The City of Tampa issued an IFB in April 2026 for Advanced Life Support Medications (Bid No. 26P00188, due April 8, 2026, estimated value $40,000), requiring supply of Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue with nine-month minimum expiration dates and ten-day delivery; the solicitation included a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), effective July 1, 2026, with a two-year term and price competitiveness weighted at 75 percent of evaluation. The Texas HHS Commission posted an RFI on April 3, 2026, to assess vendor capability for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels; no formal award or budget is attached to the RFI stage.